Description
LOXO-101 (larotrectinib) is an inhibitor of tropomyosin kinase receptors TRKA, TRKB, and TRKC. It exhibits strong antitumor activity in TRK fusion-positive cancers. In TRK fusion-positive cancers, NTRK genes which are responsible for encoding TRK are fused, leading to the transcription of chimeric TRK proteins with overexpressed kinase function.